```html

Jerusalem Belly (Mediterranean Fever)

Overview

Jerusalem belly, also known as Mediterranean fever or Familial Mediterranean Fever (FMF), is a hereditary autoinflammatory disorder characterized by recurrent episodes of fever and painful inflammation of the abdominal cavity, chest, and joints. The condition is most common among people of Mediterranean ancestry—including populations from Turkey, Armenia, Arab countries, and Sephardic Jews—but it can affect individuals of any ethnicity.

Key facts

• Prevalence: Approximately 1 in 1,000 to 1 in 5,000 individuals in high‑risk regions; up to 150,000 people worldwide are estimated to carry disease‑causing mutations in the MEFV gene.<sup>[1] WHO, 2023</sup>
• Age of onset: Typically before age 20, with 60–70 % of patients experiencing their first attack in childhood.
• Inheritance: Autosomal recessive—both parents must carry a mutated copy of the MEFV gene for a child to develop FMF.

Symptoms

Symptoms occur in “attacks” that last from a few hours to several days, followed by periods of remission that can range from weeks to months. The intensity and combination of symptoms vary between individuals.

Complete Symptom List

• Fever – Sudden rise to 38–40 °C (100.4–104 °F); often the first sign of an attack.
• Abdominal pain – Sharp, cramping pain, usually in the periumbilical or lower abdominal region; can mimic appendicitis.
• Chest pain – Pleuritic pain (sharp, worsens with breathing) caused by inflammation of the lining of the lungs (pleuritis).
• Joint pain – Typically involves the knees, ankles, or elbows; swelling is less common than in rheumatoid arthritis.
• Skin rash – Erysipeloid rash (red, raised patches) over the feet or legs during attacks.
• Muscle aches (myalgia) – Generalized soreness, especially in the back and thighs.
• Headache – May accompany fever or occur independently.
• Fatigue – Persistent tiredness that can last weeks after an attack resolves.
• Proteinuria – Presence of protein in urine, indicating early kidney involvement (often asymptomatic).

Causes and Risk Factors

Genetic Origin

FMF is caused by mutations in the MEFV gene, which encodes the protein pyrin. Pyrin regulates the inflammatory response; defective pyrin leads to uncontrolled activation of the innate immune system, resulting in the periodic fever spikes and serosal inflammation characteristic of the disease.<sup>[2] NIH, 2022</sup>

Common Mutations

• M694V – most severe, associated with higher risk of kidney disease.
• V726A, M680I, E148Q – milder phenotypes but still clinically significant.

Who Is at Risk?

• Individuals of Mediterranean descent (Turkish, Armenian, Arab, Jewish, Italian, Greek).
• Anyone with a family history of recurrent fevers, unexplained abdominal pain, or known MEFV mutations.
• Carriers (one mutated gene) are usually asymptomatic but may experience milder attacks.

Diagnosis

Because FMF mimics many other acute abdominal or rheumatologic conditions, a careful clinical evaluation is essential.

Step‑by‑Step Diagnostic Approach

1. Clinical history – Recurrent fever episodes, characteristic symptom pattern, age of onset, family history.
2. Physical examination – Assess for abdominal tenderness, pleuritic pain, joint swelling.
3. Laboratory tests during an attack
   • Elevated acute‑phase reactants: C‑reactive protein (CRP) & erythrocyte sedimentation rate (ESR).
   • Leukocytosis (high white‑blood‑cell count).
   • Serum amyloid A (SAA) – important for monitoring risk of amyloidosis.
4. Genetic testing – Sequencing of the MEFV gene confirms the diagnosis in > 85 % of suspected cases.<sup>[3] Cleveland Clinic, 2023</sup>
5. Exclusion of other conditions – Imaging (ultrasound, CT) to rule out appendicitis, ovarian torsion, or inflammatory bowel disease.

Diagnostic Criteria

The Tel‑Hashomer criteria (clinical) and the recent Eurofever/PRINTO classification are commonly used. A combination of typical symptoms plus a pathogenic MEFV mutation yields the highest diagnostic confidence.

Treatment Options

Effective treatment dramatically reduces attack frequency, prevents complications, and improves quality of life.

First‑Line Medication: Colchicine

• Mechanism: Stabilizes microtubules, diminishing neutrophil activity and inflammation.
• Dosage: 0.5–2 mg daily (adjusted for age, weight, renal function).
• Response: ≥ 70 % of patients become attack‑free with regular use.<sup>[4] Mayo Clinic, 2023</sup>
• Side effects: Gastro‑intestinal upset, diarrhea, rare myopathy or bone‑marrow suppression; monitor blood counts and renal function.

Colchicine‑Resistant or Intolerant Cases

About 5–10 % of patients do not achieve control with colchicine.

• Interleukin‑1 (IL‑1) inhibitors – Anakinra (daily subcutaneous), Canakinumab (every 4–8 weeks). Shown to reduce attack frequency > 90 % in clinical trials.<sup>[5] NEJM, 2021</sup>
• TNF‑α blockers – Etanercept or infliximab (off‑label, limited data).
• IL‑6 blockade – Tocilizumab (experimental).

Lifestyle and Supportive Measures

• Hydration and balanced diet – adequate fluid intake during attacks.
• Pain control – acetaminophen or short courses of NSAIDs (if no contraindication).
• Stress management – relaxation techniques, adequate sleep.

Living with Jerusalem Belly (Mediterranean Fever)

Daily Management Tips

• Take colchicine consistently – Even when you feel well, missing doses can trigger attacks.
• Regular monitoring – Blood tests every 3–6 months for CBC, liver/kidney function, and SAA levels.
• Know your triggers – Physical stress, extreme temperatures, dehydration, and certain infections can precipitate attacks.
• Keep a symptom diary – Record fever spikes, pain locations, medication timing, and possible triggers. This helps physicians adjust therapy.
• Vaccinations – Stay up‑to‑date (influenza, COVID‑19, pneumococcal) to lower infection‑related flare risk.
• Exercise safely – Low‑impact activities (walking, swimming) improve cardiovascular health without over‑taxing joints.
• Psychological support – Chronic disease can cause anxiety; counseling or support groups (e.g., FMF patient associations) are beneficial.

Family Planning

FMF does not usually affect fertility. However, colchicine is considered safe in pregnancy at standard doses, and discontinuation can worsen disease activity. Women should discuss medication plans with a maternal‑fetal specialist.

Prevention

Because FMF is genetic, primary prevention is not possible, but secondary measures can reduce attack frequency and long‑term complications.

• Early genetic counseling for families with known MEFV mutations.
• Strict adherence to colchicine therapy.
• Prompt treatment of infections (e.g., urinary tract, respiratory) that may trigger flares.
• Avoid excessive alcohol and dehydration.
• Regular follow‑up with a rheumatologist or geneticist familiar with FMF.

Complications

When inadequately treated, FMF can lead to serious organ damage.

• AA amyloidosis – Deposition of serum amyloid A protein in kidneys, liver, spleen, or heart; the leading cause of morbidity and mortality. Risk correlates with persistent high SAA levels.<sup>[6] CDC, 2022</sup>
• Chronic kidney disease – Often secondary to amyloid deposition; may progress to end‑stage renal disease requiring dialysis.
• Infertility – Rare, usually due to scarring from repeated peritoneal inflammation.
• Cardiovascular disease – Chronic inflammation may accelerate atherosclerosis.
• Growth retardation in children – Recurrent inflammation can affect height if disease is uncontrolled.

When to Seek Emergency Care

References

1. World Health Organization. “Familial Mediterranean Fever: Global Overview.” 2023.
2. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases. “MEFV Gene and FMF.” 2022.
3. Cleveland Clinic. “Familial Mediterranean Fever (FMF).” Updated 2023.
4. Mayo Clinic. “Colchicine: Uses, Dosage, Side Effects.” 2023.
5. Griffiths et al. “IL‑1 blockade in colchicine‑resistant FMF: Randomized trial.” New England Journal of Medicine, 2021.
6. Centers for Disease Control and Prevention. “AA Amyloidosis and Kidney Disease.” 2022.

```